STOCK TITAN

Veracyte (NASDAQ: VCYT) GC reports RSU tax share withholding

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Veracyte, Inc. senior vice president and general counsel Annie McGuire reported a tax-related share disposition tied to restricted stock units. On March 2, 2026, 6,902 shares of common stock at $36.01 per share were withheld to cover tax obligations in connection with RSU vesting and did not represent a sale. After this withholding, she directly owned 101,364 shares of Veracyte common stock.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McGuire Annie

(Last) (First) (Middle)
6000 SHORELINE COURT, SUITE 300

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/02/2026 F(1) 6,902 D $36.01 101,364 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on March 2, 2026 and does not represent a sale.
Remarks:
/s/ Jonathan Wygant, as attorney-in-fact 03/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veracyte (VCYT) report for Annie McGuire?

Veracyte reported that SVP and general counsel Annie McGuire had 6,902 shares of common stock withheld on March 2, 2026. The shares were retained by the company solely to satisfy tax withholding obligations from vesting restricted stock units, and the filing states this was not a sale.

Did the Veracyte (VCYT) Form 4 show an open-market sale of shares?

No, the Form 4 explicitly states the transaction does not represent a sale. The 6,902 shares of Veracyte common stock were withheld to satisfy Annie McGuire’s tax withholding obligations related to vesting restricted stock units on March 2, 2026.

How many Veracyte (VCYT) shares does Annie McGuire own after the Form 4 transaction?

After the tax-withholding disposition, Annie McGuire directly owns 101,364 shares of Veracyte common stock. This figure reflects her remaining direct holdings following the withholding of 6,902 shares to cover tax obligations from vesting restricted stock units.

What does transaction code F mean in the Veracyte (VCYT) Form 4?

Transaction code F indicates a tax-withholding disposition where shares are delivered to satisfy tax or exercise obligations. In this Veracyte filing, 6,902 shares were withheld from Annie McGuire’s vesting restricted stock units to cover tax liabilities, rather than being sold in the market.

What was the implied price per share in the Veracyte (VCYT) insider transaction?

The Form 4 lists a price of $36.01 per share for the 6,902 Veracyte shares withheld. This figure is used for the tax-withholding disposition associated with Annie McGuire’s vesting restricted stock units on March 2, 2026, and not for an open-market trade.
Veracyte

NASDAQ:VCYT

VCYT Rankings

VCYT Latest News

VCYT Latest SEC Filings

VCYT Stock Data

2.77B
78.54M
Diagnostics & Research
Services-medical Laboratories
Link
United States
SOUTH SAN FRANCISCO